|
1
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bever KM and Le DT: An expanding role for
immunotherapy in colorectal cancer. J Natl Compr Canc Netw.
15:401–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bode AM, Dong Z and Wang H: Cancer
prevention and control: Alarming challenges in China. Natl Sci Rev.
3:117–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jacome AA and Eng C: Role of immune
checkpoint inhibitors in the treatment of colorectal cancer: Focus
on nivolumab. Expert Opin Biol Ther. 19:1247–1263. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi J, Yu Y, Akilli Ozturk O, Holland JD,
Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I and
Birchmeier W: New Wnt/β-catenin target genes promote experimental
metastasis and migration of colorectal cancer cells through
different signals. Gut. 65:1690–1701. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee K, Lindsey AS, Li N, Gary B, Andrews
J, Keeton AB and Piazza GA: β-catenin nuclear translocation in
colorectal cancer cells is suppressed by PDE10A inhibition, cGMP
elevation, and activation of PKG. Oncotarget. 7:5353–5365. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larriba MJ, Valle N, Palmer HG,
Ordóñez-Morán P, Alvarez-Díaz S, Becker KF, Gamallo C, de Herreros
AG, González-Sancho JM and Muñoz A: The inhibition of
Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is
abrogated by Snail1 in human colon cancer cells. Endocr Relat
Cancer. 14:141–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arce L, Yokoyama NN and Waterman ML:
Diversity of LEF/TCF action in development and disease. Oncogene.
25:7492–7504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Li Y, Wu Y, Shi K, Bing L and Hao
J: Wnt/β-catenin signaling pathway upregulates c-Myc expression to
promote cell proliferation of P19 teratocarcinoma cells. Anat Rec
(Hoboken). 295:2104–2113. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dow LE, O'Rourke KP, Simon J,
Tschaharganeh DF, van Es JH, Clevers H and Lowe SW: Apc restoration
promotes cellular differentiation and reestablishes crypt
homeostasis in colorectal cancer. Cell. 161:1539–1552. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phelps RA, Chidester S, Dehghanizadeh S,
Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW and
Jones DA: A two-step model for colon adenoma initiation and
progression caused by APC loss. Cell. 137:623–634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang YS, Jeong EJ, Seok HJ, Kim SK, Hwang
JS, Choi ML, Jo DG, Kim Y, Choi J, Lee YJ, et al: Cks1 regulates
human hepatocellular carcinoma cell progression through osteopontin
expression. Biochem Biophys Res Commun. 508:275–281. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ouyang X, Huang Y, Jin X, Zhao W, Hu T, Wu
F and Huang J: Osteopontin promotes cancer cell drug resistance,
invasion, and lactate production and is associated with poor
outcome of patients with advanced non-small-cell lung cancer. Onco
Targets Ther. 11:5933–5941. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferreira LB, Eloy C, Pestana A, Lyra J,
Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E and
Soares P: Osteopontin expression is correlated with differentiation
and good prognosis in medullary thyroid carcinoma. Eur J
Endocrinol. 174:551–561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu C, Sun L, Jiang C, Zhou H, Gu L, Liu Y
and Xu Q: SPP1, analyzed by bioinformatics methods, promotes the
metastasis in colorectal cancer by activating EMT pathway. Biomed
Pharmacother. 91:1167–1177. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang RH, Quan YJ, Chen JH, Wang TF, Xu M,
Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes
cell migration and invasion, and inhibits apoptosis and autophagy
in colorectal cancer by activating the p38 MAPK signaling pathway.
Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xin B, He X, Wang J, Cai J, Wei W, Zhang T
and Shen X: Nerve growth factor regulates CD133 function to promote
tumor cell migration and invasion via activating ERK1/2 signaling
in pancreatic cancer. Pancreatology. 16:1005–1014. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Likui W, Hong W and Shuwen Z: Clinical
significance of the upregulated osteopontin mRNA expression in
human colorectal cancer. J Gastrointest Surg. 14:74–81. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Irby RB, McCarthy SM and Yeatman TJ:
Osteopontin regulates multiple functions contributing to human
colon cancer development and progression. Clin Exp Metastasis.
21:515–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rohde F, Rimkus C, Friederichs J,
Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR and Janssen
KP: Expression of osteopontin, a target gene of de-regulated Wnt
signaling, predicts survival in colon cancer. Int J Cancer.
121:1717–1723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Denhardt DT and Guo X: Osteopontin: A
protein with diverse functions. FASEB J. 7:1475–1482. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Denhardt DT, Giachelli CM and Rittling SR:
Role of osteopontin in cellular signaling and toxicant injury. Annu
Rev Pharmacol Toxicol. 41:723–749. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramankulov A, Lein M, Kristiansen G, Meyer
HA, Loening SA and Jung K: Elevated plasma osteopontin as marker
for distant metastases and poor survival in patients with renal
cell carcinoma. J Cancer Res Clin Oncol. 133:643–652. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avirovic M, Matusan-Ilijas K, Damante G,
Fabrro D, Cerović R, Juretić M, Grahovac B, Jonjić N and Lučin K:
Osteopontin expression is an independent factor for poor survival
in oral squamous cell carcinoma: A computer-assisted analysis on
TMA sections. J Oral Pathol Med. 42:620–626. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Loosen SH, Roderburg C, Kauertz KL,
Pombeiro I, Leyh C, Benz F, Vucur M, Longerich T, Koch A,
Braunschweig T, et al: Elevated levels of circulating osteopontin
are associated with a poor survival after resection of
cholangiocarcinoma. J Hepatol. 67:749–757. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei R, Wong JPC, Lyu P, Xi X, Tong O,
Zhang SD, Yuen HF, Shirasawa S and Kwok HF: In vitro and clinical
data analysis of Osteopontin as a prognostic indicator in
colorectal cancer. J Cell Mol Med. 22:4097–4105. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Likui W, Hong W, Shuwen Z, Yuangang Y and
Yan W: The potential of osteopontin as a therapeutic target for
human colorectal cancer. J Gastrointest Surg. 15:652–659. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang J, Pan C, Hu H, Zheng S and Ding L:
Osteopontin-enhanced hepatic metastasis of colorectal cancer cells.
PLoS One. 7:e479012012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McManus EJ, Sakamoto K, Armit LJ,
Ronaldson L, Shpiro N, Marquez R and Alessi DR: Role that
phosphorylation of GSK3 plays in insulin and Wnt signalling defined
by knockin analysis. EMBO J. 24:1571–1583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Robertson BW and Chellaiah MA: Osteopontin
induces beta-catenin signaling through activation of Akt in
prostate cancer cells. Exp Cell Res. 316:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
El-Tanani MK, Barraclough R, Wilkinson MC
and Rudland PS: Regulatory region of metastasis-inducing DNA is the
binding site for T cell factor-4. Oncogene. 20:1793–1797. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Van der Jeught K, Xu HC, Li YJ, Lu XB and
Ji G: Drug resistance and new therapies in colorectal cancer. World
J Gastroenterol. 24:3834–3848. 2018. View Article : Google Scholar : PubMed/NCBI
|
